Dexpramipexole
Dexpramipexole is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
172 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | 10 | 21 | 17 | 26 | 74 |
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | 4 | 9 | 11 | 7 | 30 |
| Syndrome | D013577 | — | — | 1 | 4 | 9 | 8 | 6 | 28 |
| Psychomotor agitation | D011595 | — | — | — | 4 | 9 | 9 | 6 | 27 |
| Depression | D003863 | — | F33.9 | — | 5 | 3 | 9 | 5 | 22 |
| Healthy volunteers/patients | — | — | — | 12 | — | — | 1 | 1 | 14 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 4 | 2 | 5 | 2 | 13 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 2 | 1 | 3 | — | 6 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 3 | — | 2 | — | 5 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | — | 2 | 1 | 3 |
Show 15 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | 7 | 4 | 2 | — | 1 | 12 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | 7 | 4 | 2 | — | 1 | 12 |
| Sclerosis | D012598 | — | — | 2 | 4 | 2 | — | 1 | 7 |
| Eosinophilia | D004802 | HP_0001880 | D72.1 | — | 2 | 4 | — | — | 6 |
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | 4 | — | — | 5 |
| Pulmonary eosinophilia | D011657 | EFO_0007257 | J82.81 | — | 1 | 4 | — | — | 5 |
| Anhedonia | D059445 | — | R45.84 | — | 1 | 2 | — | — | 3 |
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | 1 | 1 | — | — | 2 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | 1 | — | — | 1 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nervous system diseases | D009422 | — | G00-G99 | — | 2 | — | — | 1 | 3 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 1 | 2 | — | — | — | 3 |
| Compulsive personality disorder | D003193 | — | F60.5 | 1 | 2 | — | — | — | 3 |
| Central nervous system diseases | D002493 | HP_0002011 | G96.9 | — | 2 | — | — | — | 2 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | 2 | — | — | — | 2 |
| Movement disorders | D009069 | HP_0100022 | — | — | 2 | — | — | — | 2 |
| Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | 2 | — | — | — | 2 |
| Parkinsonian disorders | D020734 | HP_0001300 | G20.C | — | 1 | — | — | 1 | 2 |
| Dyskinesias | D020820 | HP_0002310 | G24 | — | 2 | — | — | — | 2 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 1 | — | — | 1 | 2 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | 1 | 2 |
| Compulsive behavior | D003192 | — | R46.81 | 1 | — | — | — | — | 1 |
| Cocaine-related disorders | D019970 | — | F14 | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Chronic pain | D059350 | HP_0012532 | — | 1 | — | — | — | — | 1 |
| Basal ganglia diseases | D001480 | HP_0002134 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Shy-drager syndrome | D012791 | EFO_1001050 | — | — | — | — | — | 1 | 1 |
| Multiple system atrophy | D019578 | — | — | — | — | — | — | 1 | 1 |
| Neurologic gait disorders | D020233 | HP_0003376 | R26.1 | — | — | — | — | 1 | 1 |
| Huntington disease | D006816 | Orphanet_399 | G10 | — | — | — | — | 1 | 1 |
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | — | — | — | — | 1 | 1 |
| Corticobasal degeneration | D000088282 | — | — | — | — | — | — | 1 | 1 |
| Emotions | D004644 | — | — | — | — | — | — | 1 | 1 |
| Motivation | D009042 | — | — | — | — | — | — | 1 | 1 |
| Reward | D012201 | — | — | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 1 | 1 |
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dexpramipexole |
| INN | dexpramipexole |
| Description | Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCN[C@@H]1CCc2nc(N)sc2C1 |
Identifiers
| PDB | — |
| CAS-ID | 104617-86-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL249420 |
| ChEBI ID | — |
| PubChem CID | 59868 |
| DrugBank | — |
| UNII ID | WI638GUS96 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 408 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use